3
Participants
Start Date
May 7, 2020
Primary Completion Date
November 5, 2021
Study Completion Date
December 13, 2021
ICP-022
ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
Peking University Third Hospital, Beijing
The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou
Affiliated Tumor Hospital of Harbin Medical University, Haerbin
Jiangsu Province Hospital, Nanjing
Shengjing Hospital of China Medical University, Shenyang
The Fourth Hospital of Hebei Medical University, Hebei
Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), Tianjin
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY